

# Biomarker Testing Services Market Size, Share & Trends Analysis Report By Services (Biomarker Assay Development & Validation, Flow Cytometry), By Enduser (Research Institutes, CROS), By Region, And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/B20AC962A144EN.html

Date: October 2022

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: B20AC962A144EN

#### **Abstracts**

This report can be delivered to the clients within 3 Business Days

Biomarker Testing Services Market Growth & Trends

The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030, registering a CAGR of 6.9% during the forecast period, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-



related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights

The biomarker assay development & validation segment by service was expected to hold the largest share of 59.8% in 2021. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service

Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 44.0% in 2021, owing to the rising investment in R&D by these companies

North America held the largest share of 46.2% in 2021, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth



#### **Contents**

#### **CHAPTER 1. METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation & Scope
  - 1.1.1. Services
  - 1.1.2. End-user
  - 1.1.3. Regional scope
  - 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
  - 1.3.1. Purchased database
  - 1.3.2. GVR's internal database
  - 1.3.3. Secondary sources
  - 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
  - 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
  - 1.6.1. Commodity flow analysis (Model 1)
    - 1.6.1.1. Approach 1: Commodity flow approach
  - 1.6.2. Volume price analysis (Model 2)
    - 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
  - 1.9.1. Objective
  - 1.9.2. Objective

#### **CHAPTER 2. EXECUTIVE SUMMARY**

2.1. Market Outlook

## CHAPTER 3. BIOMARKER TESTING SERVICES MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent market outlook



- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
  - 3.3.1. Market driver analysis
    - 3.3.1.1. Increasing demand for biomarker testing for cancer detection
    - 3.3.1.2. Increasing R&D activities
- 3.3.1.3. Growing burden of chronic and infectious diseases supporting demand for biomarker testing
  - 3.3.2. Market restraint analysis
    - 3.3.2.1. High capital investments and lengthy timelines for biomarker development
- 3.4. Biomarker Testing Services Market Analysis Tools
  - 3.4.1. Industry Analysis Porter's
  - 3.4.2. PESTEL Analysis
  - 3.4.3. Major Deals & Strategic Alliances Analysis
  - 3.4.3.1. Mergers and Acquisition
  - 3.4.3.2. Expansions
  - 3.4.3.3. Agreements and Collaborations
  - 3.4.3.4. Product and Service Launches
- 3.5. Covid-19 Impact and Reformation Strategy

# CHAPTER 4. BIOMARKER TESTING SERVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1. Definitions and Scope
- 4.2. Biomarker Testing Services Market Share, 2021 & 2030
  - 4.2.1. Biomarker Assay Development & Validation
- 4.2.1.1. Biomarker assay development & validation market estimates and forecast 2018 to 2030 (USD Billion)
  - 4.2.2. Flow cytometry
  - 4.2.2.1. Flow cytometry market estimates and forecast 2018 to 2030 (USD Billion)
  - 4.2.3. Others
    - 4.2.3.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

## CHAPTER 5. BIOMARKER TESTING SERVICES MARKET: END-USER ESTIMATES & TREND ANALYSIS

- 5.1. Definitions and Scope
- 5.2. Biomarker Testing Services Market Share, 2021 & 2030
  - 5.2.1. Pharmaceutical and biotechnology companies



- 5.2.1.1. Pharmaceutical and biotechnology companies market estimates and forecast 2018 to 2030 (USD Billion)
  - 5.2.2. Research Institutes
- 5.2.2.1. Research Institutes market estimates and forecast 2018 to 2030 (USD Billion)
  - 5.2.3. CROS
    - 5.2.3.1. CROS market estimates and forecast 2018 to 2030 (USD Billion)

## CHAPTER 6. BIOMARKER TESTING SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 6.1. Regional market share analysis, 2021& 2030
- 6.2. North America
  - 6.2.1. U.S.
    - 6.2.1.1. U.S. Market estimates and forecast, 2018 2030
  - 6.2.2. Canada
    - 6.2.2.1. Canada Market estimates and forecast, 2018 2030
- 6.3. Europe
  - 6.3.1. U.K.
  - 6.3.1.1. U.K. Market estimates and forecast, 2018 2030
  - 6.3.2. Germany
    - 6.3.2.1. Germany Market estimates and forecast, 2018 2030
  - 6.3.3. France
  - 6.3.3.1. France Market estimates and forecast, 2018 2030
  - 6.3.4. Italy
  - 6.3.4.1. Italy Market estimates and forecast, 2018 2030
  - 6.3.5. Spain
    - 6.3.5.1. Spain Market estimates and forecast, 2018 2030
  - 6.3.6. Netherlands
  - 6.3.6.1. Netherlands Market estimates and forecast, 2018 2030
  - 6.3.7. Sweden
    - 6.3.7.1. Sweden Market estimates and forecast, 2018 2030
  - 6.3.8. Switzerland
    - 6.3.8.1. Switzerland Market estimates and forecast, 2018 2030
- 6.4. Asia Pacific
  - 6.4.1. Japan
    - 6.4.1.1. Japan Market estimates and forecast, 2018 2030
  - 6.4.2. China
    - 6.4.2.1. China Market estimates and forecast, 2018 2030



- 6.4.3. India
- 6.4.3.1. India Market estimates and forecast, 2018 2030
- 6.4.4. Australia
- 6.4.4.1. Australia Market estimates and forecast, 2018 2030
- 6.4.5. South Korea
- 6.4.5.1. South Korea Market estimates and forecast, 2018 2030
- 6.4.6. Thailand
- 6.4.6.1. Thailand Market estimates and forecast, 2018 2030
- 6.4.7. Malaysia
  - 6.4.7.1. Malaysia Market estimates and forecast, 2018 2030
- 6.4.8. Indonesia
- 6.4.8.1. New Zealand Market estimates and forecast, 2018 2030
- 6.4.9. Taiwan
  - 6.4.9.1. Philippines Market estimates and forecast, 2018 2030
- 6.4.10. Singapore
  - 6.4.10.1. Singapore Market estimates and forecast, 2018 2030
- 6.5. Latin America
  - 6.5.1. Brazil
  - 6.5.1.1. Brazil Market estimates and forecast, 2018 2030
  - 6.5.2. Mexico
    - 6.5.2.1. Mexico Market estimates and forecast, 2018 2030
  - 6.5.3. Argentina
  - 6.5.3.1. Argentina Market estimates and forecast, 2018 2030
  - 6.5.4. Colombia:
  - 6.5.4.1. Colombia Market estimates and forecast, 2018 2030
- 6.6. MEA
  - 6.6.1. South Africa
  - 6.6.1.1. South Africa Market estimates and forecast, 2018 2030
  - 6.6.2. Saudi Arabia
  - 6.6.2.1. Saudi Arabia Market estimates and forecast, 2018 2030
  - 6.6.3. UAE
  - 6.6.3.1. UAE Market estimates and forecast, 2018 2030
  - 6.6.4. Israel
    - 6.6.4.1. Israel Market estimates and forecast, 2018 2030

#### **CHAPTER 7. COMPETITIVE ANALYSIS**

- 7.1. Recent Developments & Impact Analysis, By Key Market Participant
- 7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging



#### Players)

- 7.3. Participant Categorization
- 7.4. Vendor Landscape
  - 7.4.1. List of Key Service Providers
  - 7.4.2. Market Differentiators
  - 7.4.3. Biomarker Testing Services Market Share Analysis

#### **CHAPTER 8. COMPETITIVE LANDSCAPE**

- 8.1. Company Profiles
  - 8.1.1. Bio Agilytix Labs
    - 8.1.1.1. Company overview
    - 8.1.1.2. Service Benchmarking
    - 8.1.1.3. Strategic initiatives
  - 8.1.2. Eurofins Scientific
    - 8.1.2.1. Company overview
    - 8.1.2.2. Financial performance
    - 8.1.2.3. Service Benchmarking
    - 8.1.2.4. Strategic initiatives
  - 8.1.3. SGS SA
    - 8.1.3.1. Company overview
    - 8.1.3.2. Financial performance
    - 8.1.3.3. Service Benchmarking
    - 8.1.3.4. Strategic initiatives
  - 8.1.4. Charles River Laboratories
    - 8.1.4.1. Company overview
    - 8.1.4.2. Financial performance
    - 8.1.4.3. Service Benchmarking
    - 8.1.4.4. Strategic initiatives
  - 8.1.5. Laboratory Corporation of America Holding
    - 8.1.5.1. Company overview
    - 8.1.5.2. Financial performance
    - 8.1.5.3. Service Benchmarking
    - 8.1.5.4. Strategic initiatives
  - 8.1.6. Thermo Fisher Scientific, Inc. (PPD, Inc.)
    - 8.1.6.1. Company overview
    - 8.1.6.2. Financial performance
    - 8.1.6.3. Service Benchmarking
  - 8.1.6.4. Strategic initiatives



- 8.1.7. ICON Plc
  - 8.1.7.1. Company overview
  - 8.1.7.2. Financial performance
  - 8.1.7.3. Service Benchmarking
  - 8.1.7.4. Strategic initiatives
- 8.1.8. IQVIA, Inc.
  - 8.1.8.1. Company overview
  - 8.1.8.2. Financial performance
  - 8.1.8.3. Service Benchmarking
  - 8.1.8.4. Strategic initiatives
- 8.1.9. Syneos Health
  - 8.1.9.1. Company overview
  - 8.1.9.2. Financial performance
  - 8.1.9.3. Service Benchmarking
  - 8.1.9.4. Strategic initiatives
- 8.1.10. Intertek Group Plc
  - 8.1.10.1. Company overview
  - 8.1.10.2. Financial performance
  - 8.1.10.3. Service Benchmarking
  - 8.1.10.4. Strategic initiatives



## **List Of Tables**

#### **LIST OF TABLES**

Table 1 List of secondary sources
Table 2 List of Abbreviations



### **List Of Figures**

#### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value chain based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Commodity flow analysis
- Fig. 9 Volume Price Analysis
- Fig. 10 Biomarker Testing Services market snapshot (2021)
- Fig. 11 Biomarker Testing Services market segmentation
- Fig. 12 Market driver relevance analysis (Current & future impact)
- Fig. 13 Market restraint relevance analysis (Current & future impact)
- Fig. 14 Penetration & growth prospect mapping
- Fig. 15 Porter's five forces analysis
- Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 17 Biomarker Testing Services market service outlook: Segment dashboard
- Fig. 18 Biomarker Testing Services market: Service movement analysis
- Fig. 19 Biomarker Assay Development & Validation market (USD Million)
- Fig. 20 Flow cytometry market (USD Million)
- Fig. 21 Others market (USD Million)
- Fig. 22 Biomarker Testing Services market End user outlook: Segment dashboard
- Fig. 23 Biomarker Testing Services market: End user movement analysis
- Fig. 24 Pharmaceutical and biotechnology companies market (USD Million)
- Fig. 25 Research Institutes market (USD Million)
- Fig. 26 CROs market (USD Million)
- Fig. 27 Regional market: Key takeaways
- Fig. 28 Regional outlook, 2021 & 2030
- Fig. 29 North America market, 2018 2030 (USD Million)
- Fig. 30 U.S. market, 2018 2030 (USD Million)
- Fig. 31 Canada Market, 2018 2030 (USD Million)
- Fig. 32 Europe Market, 2018 2030 (USD Million)
- Fig. 33 U.K Market, 2018 2030 (USD Million)
- Fig. 34 Germany Market, 2018 2030 (USD Million)
- Fig. 35 France Market, 2018 2030 (USD Million)



- Fig. 36 Italy Market, 2018 2030 (USD Million)
- Fig. 37 Spain Market, 2018 2030 (USD Million)
- Fig. 38 Netherlands Market, 2018 2030 (USD Million)
- Fig. 39 Switzerland Market, 2018 2030 (USD Million)
- Fig. 40 Sweden Market, By Service, 2018 2030 (USD Million)
- Fig. 41 Asia Pacific market, 2018 2030 (USD Million)
- Fig. 42 China market, 2018 2030 (USD Million)
- Fig. 43 India market, 2018 2030 (USD Million)
- Fig. 44 Japan market, 2018 2030 (USD Million)
- Fig. 45 Australia market, 2018 2030 (USD Million)
- Fig. 46 Malaysia market, 2018 2030 (USD Million)
- Fig. 47 Indonesia market, 2018 2030 (USD Million)
- Fig. 48 Taiwan market, 2018 2030 (USD Million)
- Fig. 49 Thailand market, 2018 2030 (USD Million)
- Fig. 50 Singapore market, 2018 2030 (USD Million)
- Fig. 51 South Korea market, 2018 2030 (USD Million)
- Fig. 52 Latin America market, 2018 2030 (USD Million)
- Fig. 53 Brazil market, 2018 2030 (USD Million)
- Fig. 54 Mexico market, 2018 2030 (USD Million)
- Fig. 55 Argentina market, 2018 2030 (USD Million)
- Fig. 56 Colombia market, 2018 2030 (USD Million)
- Fig. 57 MEA market, 2018 2030 (USD Million)
- Fig. 58 South Africa market, 2018 2030 (USD Million)
- Fig. 59 Saudi Arabia market, 2018 2030 (USD Million)
- Fig. 60 Israel market, 2018 2030 (USD Million)
- Fig. 61 UAE market, 2018 2030 (USD Million)



#### I would like to order

Product name: Biomarker Testing Services Market Size, Share & Trends Analysis Report By Services

(Biomarker Assay Development & Validation, Flow Cytometry), By End-user (Research

Institutes, CROS), By Region, And Segment Forecasts, 2022 - 2030

Product link: https://marketpublishers.com/r/B20AC962A144EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

#### **Payment**

Eirot nama:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/B20AC962A144EN.html">https://marketpublishers.com/r/B20AC962A144EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

riist name.	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970